Company: IMRX
Filing Date: 2025-06-17
Form Type: 8-K
Source: 0001790340-25-000077
Chunk: 1

Company: Immuneering Corp
Filing Date: 2025-06-17
Form: 8-K
Item: Item 8.01
Chunk 1
---
 limited to Anemia (six patients or 18%) and Neutropenia (five patients or 15%). No Grade 5 TEAEs were observed in this subset of the patient population.

Also on June 17, 2025, the Company announced that additional data from the Phase 2a portion of the Company’s atebimetinib Phase 1/2a trial was expected in the fourth quarter of 2025, and that the Company planned, pending regulatory feedback expected in the fourth quarter of 2025, to initiate a pivotal trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients in 2026, and to initiate additional clinical trial combination arms evaluating atebimetinib also in 2026.

Forward-Looking Statements

This Current Report on Form 8-K (this “ Current Report”) contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements including, without limitation, statements regarding the design and conduct of the Phase 1/2a clinical trial of atebimetinib, the timing of a planned pivotal trial evaluating atebimetinib with mGnP, plans for additional atebimetinib combination therapy trials, the timing and substance of regulatory feedback, and the timing of release of additional data from the ongoing Phase 1/2a clinical trial of atebimetinib.

These forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials.

These and other important factors discussed under the caption “ Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and filed with the U. S. Securities and Exchange Commission (the “ SEC”) on March 20, 2025, our Quarterly Report on Form 10-Q for the three-month period ended March 31, 2025 and filed with the SEC on May 5, 2025 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management’s estimates as of the date of this Current Report. While we may elect